Patents by Inventor Mark T. Martin

Mark T. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6165708
    Abstract: Detectable compounds comprising a chemically-transformable first compound covalently linked to an electrochemiluminescent compound are provided. Such compounds are useful in processes and kits that monitor the status of the first compound and derive information from such monitoring.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: December 26, 2000
    Assignee: IGEN International, Inc.
    Inventors: Pam Liang, Mark T. Martin, Liwen Dong
  • Patent number: 6121007
    Abstract: Disclosed and claimed are methods for selecting a recombinant virus, phage or cell expressing a catalytic antibody or catalytic portion thereof, or for selecting catalytic activity by a moiety. The method employs reaction-based selection for catalytic activity. The method can also be used to concentrate (increase the proportion of catalytic to non-catalytic moieties) a sample containing a catalytic moiety or viruses, phages or cells expressing a catalytic moiety. The selection or concentrating can be by employing a mechanism-based inhibitor, catalysis-accelerated movement, surface binding, changes in enthalpic component of binding as a function of temperature, or changes in binding by competition, or combinations thereof. The invention also comprehends a method for producing a recombinant virus or a cell-line expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof; and, this method can include infecting a suitable host with viruses which are screened for the expression.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: September 19, 2000
    Assignee: IGEN International Inc.
    Inventors: Mark T. Martin, Rodger G. Smith, Michael J. Darsley, David M. Simpson, Gary F. Blackburn
  • Patent number: 6120986
    Abstract: A rapid single step assay suitable for the detection or quantification of .beta.-lactam antibiotics and .beta.-lactamases. The assay can be performed directly on samples of food, such as milk and meat, blood or serum and is useful in determining the suitability of a particular antibiotic in treating a particular bacterial infection and in diagnosis of a bacterial infection. The assay is also useful in determining and quantifying .beta.-lactam antibiotic resistance. The assay can be performed on an IGEN Origen.RTM. Analyzer.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: September 19, 2000
    Assignee: IGEN International, Inc.
    Inventor: Mark T. Martin
  • Patent number: 5900237
    Abstract: Described and claimed are compounds of formula (I) wherein Y is a polypeptide, R.sub.1 is bonded to the N-terminus of Y and is hydrogen or a branched or linear, substituted or unsubstituted, C.sub.1-21 alkyl, alkene, or alkyne group, R.sub.2 is a side chain of a naturally occurring amino acid, and X is (a), (b), (c). Such compounds are useful as haptens and immunogens for the elicitation of antibodies which catalytically enhance the rate of formation or hydrolysis of primary amide bonds. Also described and claimed are methods employing the compounds and antibodies.
    Type: Grant
    Filed: May 4, 1996
    Date of Patent: May 4, 1999
    Assignee: IGEN International, Inc.
    Inventors: Andrew D. Napper, Richard C. Titmas, Mark T. Martin, Wonpyo Hong
  • Patent number: 5891648
    Abstract: Disclosed and claimed are methods for selecting a recombinant virus, phage or cell expressing a catalytic antibody or catalytic portion thereof, or for selecting catalytic activity by a moiety. The method employs reaction-based selection for catalytic activity. The method can also be used to concentrate (increase the proportion of catalytic to non-catalytic moieties) a sample containing a catalytic moiety or viruses, phages or cells expressing a catalytic moiety. The selection or concentrating can be by employing a mechanism-based inhibitor, catalysis-accelerated movement, surface binding, changes in enthalpic component of binding as a function of temperature, or changes in binding by competition, or combinations thereof. The invention also comprehends a method for producing a recombinant virus or a cell-line expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof; and, this method can include infecting a suitable host with viruses which are screened for the expression.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: April 6, 1999
    Assignee: Igen, Inc.
    Inventors: Mark T. Martin, Rodger G. Smith, Michael J. Darsley, David M. Simpson, Gary F. Blackburn
  • Patent number: 5866434
    Abstract: Graphitic nanotubes, which include tubular fullerenes (commonly called "buckytubes") and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: February 2, 1999
    Assignee: Meso Scale Technology
    Inventors: Richard J. Massey, Mark T. Martin, Liwen Dong, Ming Lu, Alan Fischer, Fabian Jameison, Pam Liang, Robert Hoch, Jonathan K. Leland
  • Patent number: 5855885
    Abstract: Disclosed and claimed are methods for producing catalytic antibodies, including human catalytic antibodies, from bacteriophage. The methods require the cloning, selection, screening, and isolation of catalytic antibodies. Also disclosed and claimed are the products themselves, the catalytic antibodies, made from the phage technology. In addition, catalytic antibodies produced from the phage technology and useful in prodrug activation are disclosed and claimed. And finally, the invention also understands the production of catalytic antibodies to phosphonates.
    Type: Grant
    Filed: July 14, 1994
    Date of Patent: January 5, 1999
    Inventors: Rodger Smith, John McCafferty, David Chiswell, Michael J. Darsley, Kevin Fitzgerald, John H. Kenten, Mark T. Martin, Richard C. Titmas, Richard O. Williams
  • Patent number: 5643713
    Abstract: Detectable compounds comprising a chemically-transformable first compound covalently linked to an electrochemiluminescent compound are provided. Such compounds are useful in processes and kits that monitor the status of the first compound and derive information from such monitoring.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 1, 1997
    Inventors: Pam Liang, Mark T. Martin, Liwen Dong
  • Patent number: 5641623
    Abstract: A rapid single step assay suitable for the detection or quantification of .beta.-lactam antibiotics and .beta.-lactamases. The assay can be performed directly on samples of food, such as milk and meat, blood or serum and is useful in determining the suitability of a particular antibiotic in treating a particular bacterial infection and in diagnosis of a bacterial infection. The assay is also useful in determining and quantifying .beta.-lactam antibiotic resistance. The assay can be performed on an IGEN Origen.sup.R Analyzer.
    Type: Grant
    Filed: January 4, 1995
    Date of Patent: June 24, 1997
    Inventor: Mark T. Martin
  • Patent number: 5631137
    Abstract: Disclosed and claimed are methods for selecting a recombinant virus, phage or cell expressing a catalytic antibody or catalytic portion thereof, or for selecting catalytic activity by a moiety. The method employs reaction-based selection for catalytic activity. The method can also be used to concentrate (increase the proportion of catalytic to non-catalytic moieties) a sample containing a catalytic moiety or viruses, phages or cells expressing a catalytic moiety. The selection or concentrating can be by employing a mechanism-based inhibitor, catalysis-accelerated movement, surface binding, changes in enthalpic component of binding as a function of temperature, or changes in binding by competition, or combinations thereof. The invention also comprehends a method for producing a recombinant virus or a cell-line expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof; and, this method can include infecting a suitable host with viruses which are screened for the expression.
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: May 20, 1997
    Assignee: Igen, Inc.
    Inventors: Mark T. Martin, Rodger G. Smith, Michael J. Darsley, David M. Simpson, Gary F. Blackburn
  • Patent number: 5571643
    Abstract: Images comprised of silver such as X-rays and electrophoresis gel bands, wherein the size and darkness of the image provides useful information, are quantitated utilizing a spectrophotometer to quantify the silver which comprises the image. An image is isolated from X-ray film or an electrophoresis gel followed by removal therefrom of any silver which is present. The removed silver is complexed to cause an optical change. A spectrophotomer is then used to measure the absorbance and the absorbance measurement is compared with a calibrated reference standard.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: November 5, 1996
    Inventors: Mark T. Martin, Rosa I. Sanchez